BTAA spoke to Professor Thomas at the recent Senate Inquiry public hearings where he outlined a national strategy for rolling out the MoST program - seeking around $35 million in funding over five years to extend the new Sydney based MoST Program to other centres. His presentation was well received.
A new drug (one of the NIBs) has shown some good results at the American Society of Neuro-oncology (ASNO) meeting according to Professor David Thomas. It is not yet available in Australia but it may be used as one of the drugs on trial in the new MoST Program within 12 months. Professor Thomas is heading up the MoST Program already being run out of St Vincent's in association with Garvan.
See the new information on the MoST Program on the BTAA Clinical Trials page , including an application form for doctors to complete and an information sheet on the program to see if you are eligible. Basically it is for those who have just about exhausted other avenues of treatment but are well enough to try the MoST Program.
Professor David Thomas is the Director and Division Head of the Genomic Cancer Medicine area of the Cancer Division of the Garvan Institute of Medical Research at the Kinghorn Cancer Centre, Darlinghurst. Sydney. He is also the Conjoint Professor, St Vincent's Clinical School, Faculty of Medicine, University of NSW, FRACP, PhD.
